{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:13:00Z","timestamp":1783912380785,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, <jats:italic>n<\/jats:italic>\u2009=\u2009270) or ischemic stroke (IS, <jats:italic>n<\/jats:italic>\u2009=\u2009327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21 and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2.41 and 4.41 for recurrent TIA and IS, respectively); additional factors for recurrent TIA were previous TIA (HR: 3.40) and microvascular disturbances (HR: 2.30); for recurrent IS arterial hypertension (HR: 4.24) and IS occurrence after MPN diagnosis (HR: 4.47). CV mortality was predicted by age over 60 years (HR: 3.98), an index IS (HR: 3.61), and the occurrence of index events after MPN diagnosis (HR: 2.62). Cytoreductive therapy was a strong protective factor (HR: 0.24). The rate of major bleeding was similar to the general population (0.90 per 100 patient-years). In conclusion, the long-term clinical outcome after TIA and IS in MPN appears even more favorable than in the general population, suggesting an advantageous benefit-risk profile of antithrombotic and cytoreductive treatment.<\/jats:p>","DOI":"10.1038\/s41408-018-0048-9","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T14:53:40Z","timestamp":1519829620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms"],"prefix":"10.1038","volume":"8","author":[{"given":"Valerio","family":"De Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Maria","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Randi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"Hernandez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palova","family":"Miroslava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Beggiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Gaetano","family":"Loscocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Cortelezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Censori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Arellano-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvis","family":"Sadjadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"48_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"48_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi, A. & Pardanani, A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 1, 97\u2013105 (2015).","journal-title":"JAMA Oncol."},{"key":"48_CR3","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","volume":"121","author":"C Patrono","year":"2013","unstructured":"Patrono, C., Rocca, B. & De Stefano, V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121, 1701\u20131711 (2013).","journal-title":"Blood"},{"key":"48_CR4","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui, T., Finazzi, G. & Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 122, 2176\u20132184 (2013).","journal-title":"Blood"},{"key":"48_CR5","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui, T. et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124, 3021\u20133023 (2014).","journal-title":"Blood"},{"key":"48_CR6","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli, R. et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 23, 2224\u20132232 (2005).","journal-title":"J. Clin. Oncol."},{"key":"48_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison, C. N. et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353, 33\u201345 (2005).","journal-title":"N. Engl. J. Med."},{"key":"48_CR8","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger, H. et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121, 1720\u20131728 (2013).","journal-title":"Blood"},{"key":"48_CR9","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2214-109X(13)70089-5","volume":"1","author":"RV Krishnamurthi","year":"2013","unstructured":"Krishnamurthi, R. V. et al. Global and regional burden of first-ever ischemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob. Health 1, e259\u2013e281 (2013).","journal-title":"Lancet Glob. Health"},{"key":"48_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui, T. et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol. 29, 761\u2013770 (2011).","journal-title":"J. Clin. Oncol."},{"key":"48_CR11","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26 Suppl 5","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26 Suppl 5, v85\u2013v99 (2015).","journal-title":"Ann. Oncol."},{"key":"48_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ajh.24607","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi, A. & Barbui, T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 92, 94\u2013108 (2017).","journal-title":"Am. J. Hematol."},{"key":"48_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano, V. et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93, 372\u2013380 (2008).","journal-title":"Haematologica"},{"key":"48_CR14","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/S0140-6736(05)66734-7","volume":"365","author":"I van Wijk","year":"2005","unstructured":"van Wijk, I. et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 365, 2098\u20132104 (2005).","journal-title":"Lancet"},{"key":"48_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00415-009-0150-9","volume":"256","author":"C Weimar","year":"2009","unstructured":"Weimar, C. et al. Long-term mortality and risk of stroke after transient ischemic attack: a hospital-based cohort study. J. Neurol. 256, 639\u2013644 (2009).","journal-title":"J. Neurol."},{"key":"48_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","volume":"42","author":"KM Mohan","year":"2011","unstructured":"Mohan, K. M. et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42, 1489\u20131494 (2011).","journal-title":"Stroke"},{"key":"48_CR17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/STROKEAHA.114.005060","volume":"45","author":"J Pennlert","year":"2014","unstructured":"Pennlert, J., Eriksson, M., Carlberg, B. & Wiklund, P. G. Long-term risk and predictors of recurrent stroke beyond the acute phase. Stroke 45, 1839\u20131841 (2014).","journal-title":"Stroke"},{"key":"48_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S. & Kearon, C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692\u2013694 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"48_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"8","author":"TA Gooley","year":"1999","unstructured":"Gooley, T. A., Leisenring, W., Crowley, J. & Storer, B. E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat. Med. 8, 695\u2013706 (1999).","journal-title":"Stat. Med."},{"key":"48_CR20","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1001\/archneur.59.10.1584","volume":"59","author":"C Weimar","year":"2002","unstructured":"Weimar, C. et al. Etiology, duration, and prognosis of transient ischemic attacks: an analysis from the German Stroke Data Bank. Arch. Neurol. 59, 1584\u20131588 (2002).","journal-title":"Arch. Neurol."},{"key":"48_CR21","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1161\/STROKEAHA.116.013988","volume":"47","author":"F Buchwald","year":"2016","unstructured":"Buchwald, F., Norrving, B. & Petersson, J. Atrial fibrillation in transient ischemic attack versus ischemic stroke: A Swedish Stroke Register (Riksstroke) Study. Stroke 47, 2456\u20132461 (2016).","journal-title":"Stroke"},{"key":"48_CR22","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","volume":"374","author":"P Amarenco","year":"2016","unstructured":"Amarenco, P. et al. One-year risk of stroke after transient ischemic attack or minor stroke. N. Engl. J. Med. 374, 1533\u20131542 (2016).","journal-title":"N. Engl. J. Med."},{"key":"48_CR23","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1161\/STROKEAHA.117.016815","volume":"48","author":"L Bergstr\u00f6m","year":"2017","unstructured":"Bergstr\u00f6m, L. et al. One-year incidence, time trends, and predictors of recurrent ischemic stroke in Sweden from 1998 to 2010: an observational study. Stroke 48, 2046\u20132051 (2017).","journal-title":"Stroke"},{"key":"48_CR24","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2016.85","volume":"30","author":"V De Stefano","year":"2016","unstructured":"De Stefano, V. et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 30, 2032\u20132038 (2016).","journal-title":"Leukemia"},{"key":"48_CR25","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 45, 2160\u20132236 (2014).","journal-title":"Stroke"},{"key":"48_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7326\/0003-4819-102-4-466","volume":"102","author":"JJ Michiels","year":"1985","unstructured":"Michiels, J. J., Abels, J., Steketee, J., van Vliet, H. H. & Vuzevski, V. D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann. Intern. Med. 102, 466\u2013447 (1985).","journal-title":"Ann. Intern. Med."},{"key":"48_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/09537100600758677","volume":"17","author":"JJ Michiels","year":"2006","unstructured":"Michiels, J. J. et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 17, 528\u2013544 (2006).","journal-title":"Platelets"},{"key":"48_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","volume":"33","author":"A Falanga","year":"2005","unstructured":"Falanga, A., Marchetti, M., Vignoli, A., Balducci, D. & Barbui, T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp. Hematol. 33, 523\u2013530 (2005).","journal-title":"Exp. Hematol."},{"key":"48_CR29","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","volume":"35","author":"A Falanga","year":"2007","unstructured":"Falanga, A. et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp. Hematol. 35, 702\u2013711 (2007).","journal-title":"Exp. Hematol."},{"key":"48_CR30","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1161\/01.STR.0000190118.02275.33","volume":"36","author":"E Touz\u00e9","year":"2005","unstructured":"Touz\u00e9, E. et al. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 36, 2748\u20132755 (2005).","journal-title":"Stroke"},{"key":"48_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004311","volume":"5","author":"LB Rinde","year":"2016","unstructured":"Rinde, L. B. et al. Ischemic stroke and risk of venous thromboembolism in the general population: the Troms\u00f8 Study. J. Am. Heart Assoc. 5, e004311 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"48_CR32","doi-asserted-by":"publisher","unstructured":"Buchwald F., Norrving B. & Petersson J. Transient ischemic attack and ischemic stroke patients with or without prior stroke. Acta Neurol. Scand. (2017). https:\/\/doi.org\/10.1111\/ane.12782.","DOI":"10.1111\/ane.12782."},{"key":"48_CR33","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo, S. et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 332, 1132\u20131136 (1995).","journal-title":"N. Engl. J. Med."},{"key":"48_CR34","doi-asserted-by":"publisher","unstructured":"Barbui T. et al. A re-appraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am. J. Haematol. (2017). https:\/\/doi.org\/10.1002\/ajh.24851.","DOI":"10.1002\/ajh.24851."},{"key":"48_CR35","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1111\/j.1538-7836.2006.02194.x","volume":"4","author":"N Maugeri","year":"2006","unstructured":"Maugeri, N. et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J. Thromb. Haemost. 4, 2593\u20132598 (2006).","journal-title":"J. Thromb. Haemost."},{"key":"48_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1160\/TH09-09-0663","volume":"104","author":"G Cella","year":"2010","unstructured":"Cella, G. et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb. Haemost. 104, 151\u2013156 (2010).","journal-title":"Thromb. Haemost."},{"key":"48_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","volume":"390","author":"L Li","year":"2017","unstructured":"Li, L., Geraghty, O. C., Mehta, Z. & Rothwell, P. M., Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390, 490\u2013499 (2017).","journal-title":"Lancet"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0048-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:34:12Z","timestamp":1671536052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0048-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0048-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]},"assertion":[{"value":"4 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"25"}}